Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 16/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 16/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 16/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 11/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 9/20 | 0.82 |
| ▸ | CFTR | P13569 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109948 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL515771 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381258 | 0.90 | PDE4A (0.92) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Ammonia Solution, Strong SCHEMBL10420651 | 0.89 | PDE4A (0.97) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7016029 | 0.89 | ADORA2A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7458212 | 0.88 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| Iodide SCHEMBL28973314 | 0.88 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9765669 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL8656750 | 0.87 | PDE4A (0.87) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL5400933 | 0.86 | PDE4A (0.91) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | claimed |
| JP-6192047-A | — | — | None | — | — | JP | disclosed |
| CN-120017041-A | Pressure converter | 力旺电子股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20150126593-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ALLERGY | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-07 | — | — | US | disclosed |
| EP-0771813-B1 | Alkylxanthine phosphonates and alkylxanthine phosphine oxydes and their use as medicines | HOECHST AG (DE) | 2002-01-16 | — | — | EP | disclosed |
| US-5728686-A | TREATMENT OF MUSCULAR DYSTROPHY | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-17 | — | — | US | disclosed |
| EP-0771813-A1 | Alkylxanthine phosphonates and alkylxanthine phosphine oxydes and their use as medicines | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-07 | — | — | EP | disclosed |
| JP-H06192047-A | HAIR TONIC | SUNSTAR INC | 1994-07-12 | — | — | JP | disclosed |
| EP-0268585-B1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | disclosed |
| US-4833146-A | BRAINS, BLOOD DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-23 | — | — | US | disclosed |
| EP-0268585-A1 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF. | HOECHST AG (DE) | 1988-06-01 | — | — | EP | disclosed |
| WO-1987000523-A2 | TERTIARY HYDROXYALKYLXANTHINES, THEIR MANUFACTURING PROCESS, MEDICINES CONTAINING THEM AND USE THEREOF | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126593-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ASTHMA AND ALLERGY | LTA4H, LTC4S, ALOX5 | PDE4A 527/4885PDE4B 713/4885PDE4C 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.